UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)

The American journal of cardiology, 2005-01, Vol.95 (2), p.254-257

2005

Volltextzugriff (PDF)

Benefits of Niacin in Patients With Versus Without the Metabolic Syndrome and Healed Myocardial Infarction (from the Coronary Drug Project)

The American journal of cardiology, 2006-02, Vol.97 (4), p.477-479

2006

Volltextzugriff (PDF)

Etanercept plus Standard Therapy for Wegener's Granulomatosis

The New England journal of medicine, 2005-01, Vol.352 (4), p.351-361

Wegener's Granulomatosis Etanercept Trial (WGET) Research Group

2005

Volltextzugriff (PDF)

Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

Journal of the American College of Cardiology, 1986-12, Vol.8 (6), p.1245-1255

1986

Volltextzugriff (PDF)

Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project

The New England journal of medicine, 1980-10, Vol.303 (18), p.1038-1041

1980

Volltextzugriff (PDF)

Design of the Wegener's Granulomatosis Etanercept Trial (WGET)

Controlled clinical trials, 2002-08, Vol.23 (4), p.450-468

2002

Volltextzugriff (PDF)

The Hypertension Prevention Trial: Assessment of the Quality of Blood Pressure Measurements

American journal of epidemiology, 1991-08, Vol.134 (4), p.379-392

1991

Volltextzugriff (PDF)

Coronary drug project : experience with niacin

European journal of clinical pharmacology, 1991, Vol.40 (1), p.S49-S51

1991

Volltextzugriff (PDF)

One-year results of the thrombolysis in myocardial infarction investigation (TIMI) phase II trial

Circulation (New York, N.Y.), 1992-02, Vol.85 (2), p.533-542

1992

Volltextzugriff (PDF)

Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial

Arthritis and rheumatism, 2003-08, Vol.48 (8), p.2299-2309

Stone, John H.

2003

Volltextzugriff (PDF)

The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project

Circulation (New York, N.Y.), 1982-08, Vol.66 (2), p.401-414

1982

Volltextzugriff (PDF)

Deaths from Injury, Violence, and Suicide in Secondary Prevention Trials of Cholesterol Lowering

The New England journal of medicine, 1991-12, Vol.325 (25), p.1813-1813

1991

Volltextzugriff (PDF)

Practical aspects of decision making in clinical trials: The coronary drug project as a case study

Controlled clinical trials, 1981-01, Vol.1 (4), p.363-376

The Coronary Drug Project Research Group

1981

Volltextzugriff (PDF)

Covariate adjustment of treatment effects in clinical trials

Controlled clinical trials, 1991-06, Vol.12 (3), p.359-366

Canner, Paul L.

1991

Volltextzugriff (PDF)

Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10

Investigative ophthalmology & visual science, 1985-07, Vol.26 (7), p.983-991

1985

Volltextzugriff (PDF)

How much data should be collected in a clinical trial? experience of the coronary drug project

Statistics in medicine, 1984-10, Vol.3 (4), p.423-432

Canner, Paul L.

1984

Volltextzugriff (PDF)

High-density lipoprotein cholesterol and prognosis after myocardial infarction

Circulation (New York, N.Y.), 1982-12, Vol.66 (6), p.1176-1178

1982

Volltextzugriff (PDF)

Monitoring Treatment Differences in Long-Term Clinical Trials

Biometrics, 1977-12, Vol.33 (4), p.603-615

Canner, Paul L.

1977

Volltextzugriff (PDF)

Monitoring of the data for evidence of adverse or beneficial treatment effects

Controlled clinical trials, 1983-01, Vol.4 (4), p.467-483

Canner, Paul L.

1983

Volltextzugriff (PDF)

Monitoring long-term clinical trials for beneficial and adverse treatment effects

Communications in statistics. Theory and methods, 1984, Vol.13 (19), p.2369-2394

CANNER, P. L

1984

Volltextzugriff (PDF)

Further aspects of data analysis

Controlled clinical trials, 1983-01, Vol.4 (4), p.485-503

Canner, Paul L.

1983

Volltextzugriff (PDF)

Brief description of the coronary drug project and other studies

Controlled clinical trials, 1983-12, Vol.4 (4), p.273-280

Canner, Paul L.

1983

Volltextzugriff (PDF)

Quality assurance and monitoring in the Hypertension Prevention Trial

Controlled clinical trials, 1989-09, Vol.10 (3), p.84S-101S

1989

Volltextzugriff (PDF)

Terminating a long-term clinical trial

Clinical pharmacology and therapeutics, 1979-01, Vol.25 (5 Pt 2), p.641

1979

Volltextzugriff (PDF)

Some Curious Results Using Minimum Variance Linear Unbiased Estimators

The American statistician, 1969-12, Vol.23 (5), p.39-40

Canner, Paul L.

1969

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(26)
Humans
(17)
Pharmacology & Pharmacy
(13)
Medicine, Research & Experimental
(12)
Research & Experimental Medicine
(12)
Male
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Middle Aged
(10)
Adult
(8)
Follow-Up Studies
(7)
Mortality
(6)
Myocardial Infarction - Drug Therapy
(6)
Myocardial Infarction - Mortality
(6)
Time Factors
(6)
Cardiac & Cardiovascular Systems
(5)
Cardiovascular System & Cardiology
(5)
Clinical Trials
(4)
Clinical Trials As Topic
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)

Benefits of Niacin in Patients With Versus Without the Metabolic Syndrome and Healed Myocardial Infarction (from the Coronary Drug Project)

Etanercept plus Standard Therapy for Wegener's Granulomatosis

Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project

Design of the Wegener's Granulomatosis Etanercept Trial (WGET)

The Hypertension Prevention Trial: Assessment of the Quality of Blood Pressure Measurements

Coronary drug project : experience with niacin

One-year results of the thrombolysis in myocardial infarction investigation (TIMI) phase II trial

Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial

The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project

Deaths from Injury, Violence, and Suicide in Secondary Prevention Trials of Cholesterol Lowering

Practical aspects of decision making in clinical trials: The coronary drug project as a case study

Covariate adjustment of treatment effects in clinical trials

Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10

How much data should be collected in a clinical trial? experience of the coronary drug project

High-density lipoprotein cholesterol and prognosis after myocardial infarction

Monitoring Treatment Differences in Long-Term Clinical Trials

Monitoring of the data for evidence of adverse or beneficial treatment effects

Monitoring long-term clinical trials for beneficial and adverse treatment effects

Further aspects of data analysis

Brief description of the coronary drug project and other studies

Quality assurance and monitoring in the Hypertension Prevention Trial

Terminating a long-term clinical trial

Some Curious Results Using Minimum Variance Linear Unbiased Estimators

Suchergebnisse filtern